

Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma

SUPPLEMENTARY MATERIALS

Supplementary Table 1: Adverse events and immune related adverse events

Type of AE	Number of patients
Non irAEs	
Total	58
Fatigue	22
Arterial hypertension	12
Bleeding	11
Diarrhea	3
Rash	3
Hand-foot skin reaction	2
Proteinuria	2
Diabetes	1
Others	35
irAEs	
Total	18
Hepatitis	6
Thyroiditis	5
Nephritis	3
Adrenalitis	2
Myositis	1
Neurological	1
Others	1

Abbreviations: irAE: immune-related adverse events.